Critical Analysis: BetterLife Pharma (BETRF) and The Competition

BetterLife Pharma (OTCMKTS: BETRF) is one of 919 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare BetterLife Pharma to similar companies based on the strength of its risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Risk & Volatility

BetterLife Pharma has a beta of 2.72, indicating that its share price is 172% more volatile than the S&P 500. Comparatively, BetterLife Pharma’s rivals have a beta of 1.14, indicating that their average share price is 14% more volatile than the S&P 500.


This table compares BetterLife Pharma and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BetterLife Pharma N/A N/A -1,217.40%
BetterLife Pharma Competitors -4,238.34% -124.21% -13.80%

Institutional and Insider Ownership

45.2% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 34.8% of BetterLife Pharma shares are owned by company insiders. Comparatively, 14.6% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for BetterLife Pharma and its rivals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BetterLife Pharma 0 0 0 0 N/A
BetterLife Pharma Competitors 5374 19622 42049 810 2.56

As a group, “Pharmaceutical preparations” companies have a potential upside of 97.70%. Given BetterLife Pharma’s rivals higher probable upside, analysts plainly believe BetterLife Pharma has less favorable growth aspects than its rivals.

Valuation & Earnings

This table compares BetterLife Pharma and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
BetterLife Pharma N/A -$27.20 million -0.21
BetterLife Pharma Competitors $1.74 billion $129.07 million 0.09

BetterLife Pharma’s rivals have higher revenue and earnings than BetterLife Pharma. BetterLife Pharma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.


BetterLife Pharma rivals beat BetterLife Pharma on 6 of the 10 factors compared.

BetterLife Pharma Company Profile

BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus. BetterLife Pharma Inc. has a research agreement with the University of California San Diego for preclinical behavioral pharmacology studies of TD-0148A, a lysergic acid diethylamide derivative solution. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.

Receive News & Ratings for BetterLife Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BetterLife Pharma and related companies with's FREE daily email newsletter.